Dr Stefano Gulià appointed as chief scientific officer of Kling Bio
Betsy Goodfellow | December 5, 2023 | Appointment | Business Services | Kling Bio, Oncology, appointment, chief scientific officer
Kling Bio has announced the appointment of Dr Stefano Gulià as chief scientific officer.
Dr Gulià has over 15 years of experience within biotherapeutics discovery and development, having worked in senior roles at Pfizer, Agenus, Flagship and RVAC, where he led the discovery and development of its first-in-class therapeutics for indications within immuno-oncology and autoimmunity.
Gulià also founded Abcuro, a biotech company focused on developing novel therapies for cancer and autoimmune diseases, holding the roles of CEO and CSO.
Michael Kowalski, chief executive officer of Kling Bio, stated: “Kling will benefit immensely from Stefano’s proven leadership skills and in-depth scientific knowledge. I am confident Stefano will help guide and execute our vision for Kling during this pivotal phase of Company growth, as we accelerate to become a world-leading drug discovery and development company.”
Commenting on his new appointment, Gulià added: “Kling’s technology is a powerful discovery engine that enables simultaneous and unbiased identification of new targets and therapeutic antibodies. I am excited about the potential to scale this clinically proven platform, focusing on cancer and emerging infectious diseases, and look forward to working with Kling’s exceptionally talented leadership team to continue building value for patients by advancing life changing medicines into the clinic.”
Betsy Goodfellow
Related Content
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
Lonza CEO to step down in 2020
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …